8-K - uniQure N.V. (0001590560) (Filer)
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - uniQure N.V filed an 8-K with the SEC on Nov 4 (a notice of a material company event).
Directly affected
- QURE uniQure N.V-2.4% 7d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that uniQure N.V belongs to, so it often moves with news about it.
- NVS Novartis AG+1.5% 15d
Novartis AG is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+12.6% 30d
AstraZeneca is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-7.3% 30d
Novo Nordisk A/S is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk-6.8% 8d
Gsk is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| QURE | +4.50% | +4.02% | base | after close | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| NVS | -1.99% | +0.99% | base | after close | after close | after close | after close |
| AZN | -7.81% | +1.49% | base | after close | after close | after close | after close |
| NVO | -4.80% | -0.53% | base | after close | after close | after close | after close |
| GSK | +0.04% | +1.60% | base | after close | after close | after close | after close |
| SNY | -6.81% | -2.11% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-04 AccNo: 0001104659-26-122362 Size: 305 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
uniQure N.V (QURE) since “8-K - uniQure N.V. (0001590560) (Filer),” compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Astrazeneca (AZN) | three days earlier | +1.49% | final price |
| Astrazeneca (AZN) | five days earlier | -7.81% | final price |
| Gsk (GSK) | three days earlier | +1.60% | final price |
| Gsk (GSK) | five days earlier | +0.04% | final price |
| Novo Nordisk A S (NVO) | three days earlier | -0.53% | final price |
| Novo Nordisk A S (NVO) | five days earlier | -4.80% | final price |
| Novartis Ag (NVS) | three days earlier | +0.99% | final price |
| Novartis Ag (NVS) | five days earlier | -1.99% | final price |
| uniQure N.V (QURE) | three days earlier | +4.02% | final price |
| uniQure N.V (QURE) | five days earlier | +4.50% | final price |
| Sanofi (SNY) | three days earlier | -2.11% | final price |
| Sanofi (SNY) | five days earlier | -6.81% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.48% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 69 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 55 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 65 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 70 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around uniQure N.V (QURE)
Companies mentioned with this story
- QURE uniQure N.V
In “8-K - uniQure N.V. (0001590560) (Filer),” uniQure N.V (QURE) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> QURE
- XLV Select Sector Spdr Tr
For “8-K - uniQure N.V. (0001590560) (Filer),” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR holds the health sector that uniQure N.V belongs to, so it often moves with news about it
- NVS Novartis Ag
Novartis Ag (NVS) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “8-K - uniQure N.V. (0001590560) (Filer).” Reason on file: Novartis AG is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news
- AZN Astrazeneca
For “8-K - uniQure N.V. (0001590560) (Filer),” Astrazeneca (AZN) is linked, with no stored direction, medium confidence. Reason on file: AstraZeneca is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news
- NVO Novo Nordisk A S
In “8-K - uniQure N.V. (0001590560) (Filer),” Novo Nordisk A S (NVO) is linked, with no stored direction, medium confidence. Reason on file: Novo Nordisk A/S is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news
- GSK Gsk
For “8-K - uniQure N.V. (0001590560) (Filer),” Gsk (GSK) is linked, with no stored direction, medium confidence. Reason on file: Gsk is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news
- SNY Sanofi
In “8-K - uniQure N.V. (0001590560) (Filer),” Sanofi (SNY) is linked, with no stored direction, medium confidence. Reason on file: Sanofi is a peer of uniQure N.V in pharmaceutical preparations; rivals often move on the same news
How “8-K - uniQure N.V. (0001590560) (Filer)” reaches uniQure N.V (QURE)
uniQure N.V (QURE) is the company in “8-K - uniQure N.V. (0001590560) (Filer),” the 4 Nov 2026 this story story.
What ties uniQure N.V (QURE) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> QURE
Also listed, Select Sector Spdr Tr (XLV): Health Care Select Sector SPDR holds the health sector that uniQure N.V belongs to, so it often moves with news about it
Dates and price levels for uniQure N.V (QURE)
NVS traded between 139.43 and 147.02 across 12 sessions. The latest close on file is 140.78. QURE traded between 21.43 and 26.63 across 7 sessions. The latest close on file is 23.89.
How solid “8-K - uniQure N.V. (0001590560) (Filer)” looks
46 out of 100
“8-K - uniQure N.V. (0001590560) (Filer)” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.